An Overview on Anticancer Drugs with Antileishmanial Activity
Leishmaniasis is a major public health problem, but so far there are no effective commercially available vaccines for this disease. Its control strategy is only reliant on therapy, but currently the drugs available for the treatment of leishmaniasis are also limited and a great concern is the rapid...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mazandaran University of Medical Sciences
2018-06-01
|
| Series: | Journal of Mazandaran University of Medical Sciences |
| Subjects: | |
| Online Access: | http://jmums.mazums.ac.ir/article-1-11163-en.html |
| _version_ | 1797943820536512512 |
|---|---|
| author | Masoud Keighobadi Javad Akhtari Mahdi Fakhar Saeed Emami Hassan Mirzaei |
| author_facet | Masoud Keighobadi Javad Akhtari Mahdi Fakhar Saeed Emami Hassan Mirzaei |
| author_sort | Masoud Keighobadi |
| collection | DOAJ |
| description | Leishmaniasis is a major public health problem, but so far there are no effective commercially available vaccines for this disease. Its control strategy is only reliant on therapy, but currently the drugs available for the treatment of leishmaniasis are also limited and a great concern is the rapid rate of resistance to common drugs. The first step in discovery and development of new drugs is to identify an appropriate drug target. Accordingly, it is important to recognize the metabolic pathways in which the leishmania parasites live and selecting a target in the parasite biological pathway, absent in the host or different from the host homolog. Discovery of new drugs requires high costs and takes a lot of time (up to 15 years). Therefore, choosing the approved drugs in the market for various diseases, including leishmaniasis is very cost-effective considering the mechanism of drug action and other aspects. Miltefosin is an effective anti-cancer agent that is also used for different types of leishmaniasis. In recent years, researchers have focused on the anti-leishmanial effects of pharmaceutical compounds or anticancer drugs to find more effective compounds with lower side effects. The present article mainly reviews the anticancer drugs that have been tested for their anti-leishmanial effects in both in vitro and in vivo conditions. |
| first_indexed | 2024-04-10T20:30:10Z |
| format | Article |
| id | doaj.art-e3490375b6464c4181ab48a61a85e621 |
| institution | Directory Open Access Journal |
| issn | 1735-9260 1735-9279 |
| language | English |
| last_indexed | 2024-04-10T20:30:10Z |
| publishDate | 2018-06-01 |
| publisher | Mazandaran University of Medical Sciences |
| record_format | Article |
| series | Journal of Mazandaran University of Medical Sciences |
| spelling | doaj.art-e3490375b6464c4181ab48a61a85e6212023-01-25T07:33:19ZengMazandaran University of Medical SciencesJournal of Mazandaran University of Medical Sciences1735-92601735-92792018-06-0128161154165An Overview on Anticancer Drugs with Antileishmanial ActivityMasoud Keighobadi0Javad Akhtari1Mahdi Fakhar2Saeed Emami3Hassan Mirzaei4 PhD Student in Pharmaceutical Sciences, Pharmaceutical Sciences Research Center, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran Assistant Professor, Department of Medical Nanotechnology, Immunogenetics Research Center, Mazandaran University of Medical Sciences, Sari, Iran Associate Professor, Department of Parasitology, Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran Professor , Department of Medicinal Chemistry, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran Assistant Professor , Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran Leishmaniasis is a major public health problem, but so far there are no effective commercially available vaccines for this disease. Its control strategy is only reliant on therapy, but currently the drugs available for the treatment of leishmaniasis are also limited and a great concern is the rapid rate of resistance to common drugs. The first step in discovery and development of new drugs is to identify an appropriate drug target. Accordingly, it is important to recognize the metabolic pathways in which the leishmania parasites live and selecting a target in the parasite biological pathway, absent in the host or different from the host homolog. Discovery of new drugs requires high costs and takes a lot of time (up to 15 years). Therefore, choosing the approved drugs in the market for various diseases, including leishmaniasis is very cost-effective considering the mechanism of drug action and other aspects. Miltefosin is an effective anti-cancer agent that is also used for different types of leishmaniasis. In recent years, researchers have focused on the anti-leishmanial effects of pharmaceutical compounds or anticancer drugs to find more effective compounds with lower side effects. The present article mainly reviews the anticancer drugs that have been tested for their anti-leishmanial effects in both in vitro and in vivo conditions.http://jmums.mazums.ac.ir/article-1-11163-en.htmlleishmaniasisdrug targetsanti-cancer drugs |
| spellingShingle | Masoud Keighobadi Javad Akhtari Mahdi Fakhar Saeed Emami Hassan Mirzaei An Overview on Anticancer Drugs with Antileishmanial Activity Journal of Mazandaran University of Medical Sciences leishmaniasis drug targets anti-cancer drugs |
| title | An Overview on Anticancer Drugs with Antileishmanial Activity |
| title_full | An Overview on Anticancer Drugs with Antileishmanial Activity |
| title_fullStr | An Overview on Anticancer Drugs with Antileishmanial Activity |
| title_full_unstemmed | An Overview on Anticancer Drugs with Antileishmanial Activity |
| title_short | An Overview on Anticancer Drugs with Antileishmanial Activity |
| title_sort | overview on anticancer drugs with antileishmanial activity |
| topic | leishmaniasis drug targets anti-cancer drugs |
| url | http://jmums.mazums.ac.ir/article-1-11163-en.html |
| work_keys_str_mv | AT masoudkeighobadi anoverviewonanticancerdrugswithantileishmanialactivity AT javadakhtari anoverviewonanticancerdrugswithantileishmanialactivity AT mahdifakhar anoverviewonanticancerdrugswithantileishmanialactivity AT saeedemami anoverviewonanticancerdrugswithantileishmanialactivity AT hassanmirzaei anoverviewonanticancerdrugswithantileishmanialactivity AT masoudkeighobadi overviewonanticancerdrugswithantileishmanialactivity AT javadakhtari overviewonanticancerdrugswithantileishmanialactivity AT mahdifakhar overviewonanticancerdrugswithantileishmanialactivity AT saeedemami overviewonanticancerdrugswithantileishmanialactivity AT hassanmirzaei overviewonanticancerdrugswithantileishmanialactivity |